Table 1. Baseline demographics and clinical parameters of enrolled patients.
| Characteristics | OT (n=7) | LTGS (n=38) | NP (n=30) | AR (n=63) | CR (n=15) | p-value | |
|---|---|---|---|---|---|---|---|
| Age (yr) | 56.1±10.6 | 57.7±9.4∥,¶ | 46.3±11.7∥ | 47.0±9.9¶ | 51.8±9.6 | <0.001 | |
| Sex (male) | 6 (85.7) | 15 (39.5) | 19 (63.3) | 43 (68.3) | 8 (53.3) | 0.192 | |
| Duration after KT (mon) | 598.9±634.0*,†,‡,§ | 198.1±79.3*,∥,¶ | 7.2±13.7†,∥ | 22.8±37.5‡,¶ | 91.7±59.9§ | <0.001 | |
| Deceased donor KT | 1 (14.3) | 6 (15.8) | 11 (36.7) | 27 (42.9) | 7 (46.7) | 0.037 | |
| ABO incompatible KT | 0 (0) | 0 (0) | 4 (13.3) | 15 (23.8) | 1 (6.7) | 0.007 | |
| HLA mismatching | 1.0±1.7 | 2.4±1.2¶ | 3.6±1.8 | 3.7±2.1 | 3.1±1.5 | 0.004 | |
| eGFR (mL/min/1.73m2) | 69.2±27.6‡,§ | 77.5±14.7¶,** | 77.2±20.6††,‡‡ | 35.8±18.9‡,¶,†† | 34.5±18.1§,**,‡‡ | <0.001 | |
| WBC (×103 cells/mm3) | 5.7±1.5 | 6.1±3.8 | 7.8±3.9 | 6.1±3.8 | 7.2±2.3 | 0.118 | |
| Indication for biopsy | N/A | N/A | N/A | ||||
| Protocol biopsy | 27 (90.0) | 9 (14.3) | 0 (0) | ||||
| Elevated creatinine levels | 3 (10.0) | 50 (79.4) | 12 (80.0) | ||||
| Proteinuria | 0 (0) | 4 (6.3) | 3 (20.0) | ||||
| Induction immunosuppression | 0.820 | ||||||
| Basiliximab | 5 (71.4) | 28 (75.7) | 24 (80.0) | 44 (69.8) | 12 (80.0) | ||
| Anti-thymocyte globulin | 2 (28.6) | 9 (24.3) | 6 (20.0) | 19 (30.2) | 3 (20.0) | ||
| Maintenance immunosuppression | |||||||
| Steroid | 0 (0) | 17 (44.7) | 28 (93.3) | 54 (85.7) | 13 (86.7) | <0.001 | |
| Tacrolimus | 0 (0) | 14 (36.8) | 30 (100) | 40 (64.5) | 8 (53.3) | <0.001 | |
| Cyclosporine | 0 (0) | 21 (55.3) | 0 (0) | 16 (25.8) | 4 (26.7) | <0.001 | |
| Mycophenolate mofetil | 0 (0) | 19 (50.0) | 30 (100) | 44 (69.8) | 10 (66.7) | <0.001 | |
| mTOR inhibitor | 0 (0) | 2 (5.4) | 1 (3.3) | 6 (9.7) | 3 (20.0) | 0.560 | |
Values are presented as number (%).
HLA, human leukocyte antigen; WBC, white blood cell; mTOR, mammalian target of rapamycin; N/A, not applicable.
*p<0.05, OT vs. LTGS; †p<0.05, OT vs. NP; ‡p<0.05, OT vs. AR; §p<0.05, OT vs. CR; ∥p<0.05, LTGS vs. NP; ¶p<0.05, LTGS vs. AR; **p<0.05, LTGS vs. CR; ††p<0.05, NP vs. AR; ‡‡p<0.05, NP vs. CR.